These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22280188)

  • 21. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
    Sonderholm J
    J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmaceutical industry--to whom is it accountable?
    Hayes TA
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183881
    [No Abstract]   [Full Text] [Related]  

  • 24. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 25. Pandora's Prescription: The Pharmaceutical Pricing
    Pederson T
    FASEB J; 2017 Nov; 31(11):4661-4662. PubMed ID: 29093000
    [No Abstract]   [Full Text] [Related]  

  • 26. EU agrees deal on cheaper drugs for developing world.
    Watson R
    BMJ; 2003 Jun; 326(7401):1229. PubMed ID: 12791716
    [No Abstract]   [Full Text] [Related]  

  • 27. The pharmaceutical industry--to whom is it accountable?
    Summers WK; Driscoll J; Orient JM
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183883
    [No Abstract]   [Full Text] [Related]  

  • 28. [Parallel import of drugs for better and for worse].
    Krabbe U
    Ugeskr Laeger; 2004 Feb; 166(7):611. PubMed ID: 15005051
    [No Abstract]   [Full Text] [Related]  

  • 29. Link cost to clinical outcome.
    Norris J
    BMJ; 2007 May; 334(7601):968. PubMed ID: 17493992
    [No Abstract]   [Full Text] [Related]  

  • 30. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 32. EU offers incentives to firms to produce medicines for children.
    Watson R
    BMJ; 2006 Jun; 332(7554):1352. PubMed ID: 16763236
    [No Abstract]   [Full Text] [Related]  

  • 33. NIH urged to cap profits made on publicly funded research.
    Macilwain C
    Nature; 2000 Jul; 406(6791):5. PubMed ID: 10894508
    [No Abstract]   [Full Text] [Related]  

  • 34. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 37. Protect pharmaceutical innovation.
    Musselwhite LW; Andrews J
    Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
    [No Abstract]   [Full Text] [Related]  

  • 38. More drugs, less protection.
    Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
    [No Abstract]   [Full Text] [Related]  

  • 39. European collaboration on relative effectiveness will move into the next phase.
    Goettsch W
    J Comp Eff Res; 2013 Jan; 2(1):5-6. PubMed ID: 24236514
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug pricing. NIH report knocks tax on blockbusters.
    Kaiser J
    Science; 2001 Aug; 293(5535):1575. PubMed ID: 11533456
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.